FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025164808> ?p ?o ?g. }

• W3025164808 endingPage "175628642091500" @default.
• W3025164808 startingPage "175628642091500" @default.
• W3025164808 abstract "Introduction: We report safety and efficacy in patients treated with dimethyl fumarate (DMF) for ~9 years in ENDORSE. Lymphocyte analysis data are also reported. Methods: Incidence of serious adverse events (SAEs), discontinuations due to adverse events (AEs), annualized relapse rate (ARR) and Expanded Disability Status Scale (EDSS) score were assessed. Patients were treated with DMF 240 mg twice daily (BID): placebo (PBO)/DMF (PBO for years 0–2 /DMF for years 3–9) or continuous (DMF/DMF) treatment; newly diagnosed patients were included. Annual magnetic resonance imaging (MRI) was evaluated in patients from the MRI cohort of DEFINE/CONFIRM. For the lymphocyte analysis, data from first DMF exposure were analyzed. Results: Of 2079 DEFINE/CONFIRM completers, 1736 enrolled and received ⩾1 dose of DMF. The MRI cohort included 530 patients. In the overall population, 527 (30%) patients experienced SAEs; most were fall and urinary tract infection. Over 9 years on DMF treatment, adjusted ARR remained low (⩽0.20). In patients treated with PBO in years 0–2, decreased ARR was apparent as early as year 3. Of DMF/DMF and PBO/DMF patients, 73% and 74%, respectively, had no 24-week confirmed disability progression. Most patients (~70%) had no new T1 or new/newly enlarging T2 lesions compared with previous MRI scans after 7 years treatment with DMF; the annual number of new T1 hypointense lesions and new/newly enlarging T2 hyperintense lesions were 0.6–0.8 and 0.9–2.0, respectively. Mean percentage brain volume change from ENDORSE baseline (6 years treatment in ENDORSE) was −1.32% (range −1.60% to −1.05%). Of the 2513 patients with lymphocyte assessments, 2470 had ⩾1 post-baseline measurement, 53 developed severe prolonged lymphopenia and were followed for up to 11 years; incidence of serious infection was not higher than in patients with absolute lymphocyte count (ALC) always ⩾ lower limit of normal (LLN). In patients with lymphopenia while on DMF and ALC < 0.91 × 10 9 /L at discontinuation ( n = 138), median time to ALC ⩾ LLN was 7 weeks post-discontinuation. Conclusions: Sustained safety and efficacy of DMF was observed in patients continuing on treatment for up to 11 years, supporting DMF as a long-term treatment option for patients with RRMS. Trial registration: ClinicalTrials.gov identifiers, NCT00835770 (ENDORSE); NCT00420212 (DEFINE); NCT00451451 (CONFIRM)." @default.
• W3025164808 created "2020-05-21" @default.
• W3025164808 creator A5008598861 @default.
• W3025164808 creator A5023187359 @default.
• W3025164808 creator A5029734617 @default.
• W3025164808 creator A5035320001 @default.
• W3025164808 creator A5054874316 @default.
• W3025164808 creator A5062220148 @default.
• W3025164808 creator A5068628840 @default.
• W3025164808 creator A5077310868 @default.
• W3025164808 date "2020-01-01" @default.
• W3025164808 modified "2023-10-16" @default.
• W3025164808 title "Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE" @default.
• W3025164808 cites W1965545788 @default.
• W3025164808 cites W1967838438 @default.
• W3025164808 cites W1982614515 @default.
• W3025164808 cites W1992967362 @default.
• W3025164808 cites W1997024092 @default.
• W3025164808 cites W2007271588 @default.
• W3025164808 cites W2012934594 @default.
• W3025164808 cites W2014401649 @default.
• W3025164808 cites W2037590932 @default.
• W3025164808 cites W2090361567 @default.
• W3025164808 cites W2093009907 @default.
• W3025164808 cites W2099210971 @default.
• W3025164808 cites W2112165124 @default.
• W3025164808 cites W2115041207 @default.
• W3025164808 cites W2125097811 @default.
• W3025164808 cites W2395316927 @default.
• W3025164808 cites W4230885839 @default.
• W3025164808 doi "https://doi.org/10.1177/1756286420915005" @default.
• W3025164808 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7222239" @default.
• W3025164808 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32426039" @default.
• W3025164808 hasPublicationYear "2020" @default.
• W3025164808 type Work @default.
• W3025164808 sameAs 3025164808 @default.
• W3025164808 citedByCount "41" @default.
• W3025164808 countsByYear W30251648082020 @default.
• W3025164808 countsByYear W30251648082021 @default.
• W3025164808 countsByYear W30251648082022 @default.
• W3025164808 countsByYear W30251648082023 @default.
• W3025164808 crossrefType "journal-article" @default.
• W3025164808 hasAuthorship W3025164808A5008598861 @default.
• W3025164808 hasAuthorship W3025164808A5023187359 @default.
• W3025164808 hasAuthorship W3025164808A5029734617 @default.
• W3025164808 hasAuthorship W3025164808A5035320001 @default.
• W3025164808 hasAuthorship W3025164808A5054874316 @default.
• W3025164808 hasAuthorship W3025164808A5062220148 @default.
• W3025164808 hasAuthorship W3025164808A5068628840 @default.
• W3025164808 hasAuthorship W3025164808A5077310868 @default.
• W3025164808 hasBestOaLocation W30251648081 @default.
• W3025164808 hasConcept C120665830 @default.
• W3025164808 hasConcept C121332964 @default.
• W3025164808 hasConcept C126322002 @default.
• W3025164808 hasConcept C126838900 @default.
• W3025164808 hasConcept C142724271 @default.
• W3025164808 hasConcept C143409427 @default.
• W3025164808 hasConcept C197934379 @default.
• W3025164808 hasConcept C203014093 @default.
• W3025164808 hasConcept C204787440 @default.
• W3025164808 hasConcept C27081682 @default.
• W3025164808 hasConcept C2776819417 @default.
• W3025164808 hasConcept C2780640218 @default.
• W3025164808 hasConcept C2780892749 @default.
• W3025164808 hasConcept C2908647359 @default.
• W3025164808 hasConcept C3020694758 @default.
• W3025164808 hasConcept C61511704 @default.
• W3025164808 hasConcept C71924100 @default.
• W3025164808 hasConcept C72563966 @default.
• W3025164808 hasConcept C90924648 @default.
• W3025164808 hasConcept C99454951 @default.
• W3025164808 hasConceptScore W3025164808C120665830 @default.
• W3025164808 hasConceptScore W3025164808C121332964 @default.
• W3025164808 hasConceptScore W3025164808C126322002 @default.
• W3025164808 hasConceptScore W3025164808C126838900 @default.
• W3025164808 hasConceptScore W3025164808C142724271 @default.
• W3025164808 hasConceptScore W3025164808C143409427 @default.
• W3025164808 hasConceptScore W3025164808C197934379 @default.
• W3025164808 hasConceptScore W3025164808C203014093 @default.
• W3025164808 hasConceptScore W3025164808C204787440 @default.
• W3025164808 hasConceptScore W3025164808C27081682 @default.
• W3025164808 hasConceptScore W3025164808C2776819417 @default.
• W3025164808 hasConceptScore W3025164808C2780640218 @default.
• W3025164808 hasConceptScore W3025164808C2780892749 @default.
• W3025164808 hasConceptScore W3025164808C2908647359 @default.
• W3025164808 hasConceptScore W3025164808C3020694758 @default.
• W3025164808 hasConceptScore W3025164808C61511704 @default.
• W3025164808 hasConceptScore W3025164808C71924100 @default.
• W3025164808 hasConceptScore W3025164808C72563966 @default.
• W3025164808 hasConceptScore W3025164808C90924648 @default.
• W3025164808 hasConceptScore W3025164808C99454951 @default.
• W3025164808 hasFunder F4320308604 @default.
• W3025164808 hasLocation W30251648081 @default.
• W3025164808 hasLocation W30251648082 @default.
• W3025164808 hasLocation W30251648083 @default.
• W3025164808 hasLocation W30251648084 @default.
• W3025164808 hasOpenAccess W3025164808 @default.
• W3025164808 hasPrimaryLocation W30251648081 @default.

• next